Home
overview

 

SMi are presenting their inaugural conference on Peptide Therapeutics.

As the global Peptide Therapeutics market is expected to reach over $25 billion by 2018, the market is strongly trying to develop new peptide therapeutics and better formulations to enhance drug delivery. Even though peptides is a relatively niche market – it has a fast growth rate with many products in development.

The conference will enable you to assess biophysical characterisation such as solubility and stability in addition to reviewing analytcial techniques for monitoring peptides. Focus is on optimisation, extending the half-life and assessing alternative technologies in peptide analysis. 

Attention to detail is key in the formulation and delivery of peptides and SMi pride themselves in delivering a thorough conference with this focus in mind.  Presentations will include the assessment of new formulations and routes of administration i.e. oral, as well as reviewing compliance and efficacy challenges.

  • Gain insight into engineering novel therapeutics for optimal drug delivery
  • Hear what analytical methods can be utilised to enhance product design
  • Enhance your knowledge on strategies for the development of novel peptide therapeutics
  • Assess new formulations and routes for administration of peptides
   

• Head of Formulation
• Head of Peptide Chemistry
• Vice President, Peptides
• Vice President, Diabetes Protein and Peptide Chemistry
• Head of small molecules
• Formulation Scientist
• Global Head of Protein Engineering
• Lab Head of Early Development
 

Conference programme

8:30 Registration & Coffee

9:00 Chairs Opening Remarks

Yvonne Angell

Yvonne Angell, Director of Peptide and Protein Chemistry, Ipsen Inc.

9:10 Case Study: Development of cell-permeable therapeutic peptides targeting Wnt signalling in cancer

Annette Friebe

Annette Friebe, Head of Late Discovery , Nexigen

  • Indentification of functional peptides utilising a cellular yeast screening platform
  • Development of cell-permeable peptides with anti-tumour activity in vitro and in vivo
  • Pharmacology of the lead candidate
  • 9:50 Oral Bioavailability of Peptides

    David  Price

    David Price , Senior Director , Pfizer

  • Strategic way to bring new products to market that are more efficient and have hgher efficacy
  • Linking PK and bio-distribution of peptide therapeutics with thier pharmacological activity
  • Future directions
  • 10:30 Morning Coffee

    11:00 AQUA for peptide quantification and regulatory aspects of peptide drugs

    Dieter Deforce

    Dieter Deforce, Professor at the University of Gent, Belgium, Member of the Scientific Advice Working Party of the EMA, Gent University

  • The use of isotopically labelled synthetic peptides for the absolute quantitation of a specific peptide in a complex mixture using LC-MS/MS 
  • Some regulatory aspects will be discussed such as: generic/biosimilar, synthetic versus biologic, transdermal, oral, inhalation versus injection
  • 11:40 Strategies to enhance the development of novel peptide drugs

    Yvonne Angell

    Yvonne Angell, Director of Peptide and Protein Chemistry, Ipsen Inc.

    12:20 Networking Lunch

    13:30 Reviewing peptide engineering for the optimisation of drug like properties

    Ved Srivastava

    Ved Srivastava, Head, Peptide Chemistry, GSK

    Peptide therapy has become a key strategy of innovative drug development. One of the potential barriers to the use of the native peptides in the clinic is their short half-lives.The presentation will emphasize:

  • Attributes necessary for a commercially successful metabolic peptide
  • Strategies and tactics for the design and development of peptidase-resistant peptide analogs
  • Strategies for half-life extension to increase the duration of effect including formulation tactics for patient friendly peptide delivery
  • 14:10 SOM230: A new therapeutic modality for Cushing’s disease

    Ian Lewis

    Ian Lewis, Investigator III, Peptide Discovery Group, Exploratory Medicinal Chemistry Unit, Novartis Institutes of Biomedical Research

    14:50 Afternoon Tea

    15:20 Novel Hepcidin Agonists

    Gregory  T. Bourne

    Gregory T. Bourne, Research Fellow , Protagonist Therapeutics

  • Hepcidin is a natural peptide hormone that regulates iron homeostasis.   Hepcidin deficiency is associated with iron overload disorders such as beta-thalassemia and juvenile hemochromatosis
  •  Hepcidin is structurally complex (25-mer with 4-disulfide-cross linked beta-hairpin), difficult to synthesize, and prone to aggregation. A hepcidin agonist with suitable drug-like properties is highly desired.
  • Protagonist has utilized its proprietary VectrixTM technology platform and ‘scaffold hoping’ to identify novel hepcidin agonists with equivalent in vivo potency to hepcidin and superior physiochemical properties
  • 16:00 Extending the Half-Life of Peptides

    Yvonne Angell

    Yvonne Angell, Director of Peptide and Protein Chemistry, Ipsen Inc.

    16:40 Direct Selection of Drug-Like Macrocyclic Peptides from In Vitro Display Libraries Built with Unnatural Amino Acids

    Doug Treco

    Doug Treco, President and CEO, Ra Pharmaceuticals

  • High affinity macrocycles are isolated by affinity to targets of interest                                                                                                                                                                                                   
  • Macrocyclic peptides can adopt conformations that promote extensive intramolecular hydrogen bonding
  • Cell permeability is apparent with certain molecules
  • 17:20 Chairs Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Joel Richard

    Joel Richard, Senior Vice President, Peptides, IPSEN S.A.S

    9:10 Peptide Delivery: Where Do We Stand and What Does the Furute Hold?

    Joel Richard

    Joel Richard, Senior Vice President, Peptides, IPSEN S.A.S

    9:50 The 'Endosome Escape Trap’: a new tool to discover peptides which efficiently deliver cargoes to the cytoplasm

    Paul  Watt

    Paul Watt, CSO, Phylogica Ltd

  • Phylomers are structure-rich peptides derived from biodiverse protein fragments
  • The 'Endosome Escape Trap' allows capture of rare cell penetrating peptides which have escaped from the endosome to delivery their cargoes to the cytoplasm
  • Novel functional assays were devised quantitate the extent of delivery of protein cargoes to the cytoplasm
  • Phylogica has discovered more efficient cell penetrating peptides with this approach known as FPP’s (Functional Penetrating Peptides)
  • Ranking of peptides using such functional assays shows that some FPP’s are more efficient than conventional CPP’s
  • 10:30 Morning Coffee

    11:00 Responsive delivery systems for extended release of peptides and proteins

    Fredrik Tiberg

    Fredrik Tiberg , CEO & President , Camurus

  • Strategies for solubilisation and stability enhancement
  • Tuning release rates
  • Manufacturing and device selection
  • 11:40 Oral Peptide Drugs

    Dinesh Patel

    Dinesh Patel, President and CEO , Protagonist Therapeutics

  • Oral peptide drugs can offer excellent advantages to patients, physicians, and payers versus those targets and diseases wherein ‘injectable antibodies’ is the only available targeted therapy option.
  • Two complimentary approaches will be discussed – engineering core oral stability in peptide scaffolds vs. using specialized formulation/delivery approaches to protect and off-load the drug to the desired site of action.
  • Protagonist will disclose its progress towards ‘oral peptides for IBD’ on a clinically validated target.
  • 12:20 Networking Lunch

    13:30 Bi-Cyclic Peptides to Target Protein-Protein Interactions

    Christophe Bonny

    Christophe Bonny, CSO, Bicycle Therapeutics

    14:10 Targeting Mitochondria with Cationic Amphipathic Short Peptides

    Vincenzo Abbate

    Vincenzo Abbate, Research Associate, Kings College London

  • Mitochondria play an important role in oxidative stress, acting as the main source of Reactive Oxygen Species (ROS) generation
  • A novel class of water-soluble tetrapeptides (“SS peptides”) was recently reported, with the view to protect cells against ROS-mediated oxidative stress. These peptides consist of alternating aromatic and basic residues and are able to selectively target the inner membrane of mitochondria; furthermore, such small-peptide antioxidants are believed to penetrate cells in an energy-independent and non-saturable manner without a need for peptide transporter.
  • We have designed a series of fluorescently-labeled short peptides and have evaluated their ability to co-localize with mitochondria. The effect of different dyes on their biological behaviour was investigated. It was found that the size of the fluorescent probe strongly affected the ability of the compound to efficiently co-localize with mitochondria.
  •  Dansylated peptides were selected as models for the subsequent incorporation of iron-chelating moieties into the backbone sequence to provide a novel class of mitochondria-targeted iron chelators.
  • 14:50 Afternoon Tea

    15:20 The Use of Guanylate Cyclase-C Agonists for the Treatment of Gastrointestional Disorders

    Mark Currie

    Mark Currie, President of R&D, Chief Scientific Officer, Ironwood Pharmaceuticals Inc

  • Guanylate Cyclase-C (GCC) is a receptor expressed on the intestinal epithelial lumen surface

  • Stimulation of this receptor stimulates a visceral analgesia and fluid secretion

  • Linaclotide, a GCC agonist, is approved in the US and EU for the treatment of IBS-C

     

  • 16:00 Manufacturability - understanding the criteria to form a peptide sequence

  • What challenges are being faced for manufacturing products? 
  • Understanding the characterisation of peptides to understand thier risk profile, e.g solubility
  • Assessing how the product could behave in large scale manufacturing
  • Joel Richard

    Joel Richard, Senior Vice President, Peptides, IPSEN S.A.S

    David  Price

    David Price , Senior Director , Pfizer

    Dinesh Patel

    Dinesh Patel, President and CEO , Protagonist Therapeutics

    16:20 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    David  Price

    David Price

    Senior Director , Pfizer
    Dieter Deforce

    Dieter Deforce

    Professor at the University of Gent, Belgium, Member of the Scientific Advice Working Party of the EMA, Gent University
    Dinesh Patel

    Dinesh Patel

    President and CEO , Protagonist Therapeutics
    Doug Treco

    Doug Treco

    President and CEO, Ra Pharmaceuticals
    Mark Currie

    Mark Currie

    President of R&D, Chief Scientific Officer, Ironwood Pharmaceuticals Inc
    Ved Srivastava

    Ved Srivastava

    Head, Peptide Chemistry, GSK
    Yvonne Angell

    Yvonne Angell

    Director of Peptide and Protein Chemistry, Ipsen Inc.

    Annette Friebe

    Head of Late Discovery , Nexigen
    Annette Friebe

    Christian Luber

    Senior Scientist , Novo Nordisk Pharmaceuticals Incorporated
    Christian  Luber

    Christophe Bonny

    CSO, Bicycle Therapeutics
    Christophe Bonny

    David Price

    Senior Director , Pfizer
    David  Price

    Dieter Deforce

    Professor at the University of Gent, Belgium, Member of the Scientific Advice Working Party of the EMA, Gent University
    Dieter Deforce

    Dinesh Patel

    President and CEO , Protagonist Therapeutics
    Dinesh Patel

    Doug Treco

    President and CEO, Ra Pharmaceuticals
    Doug Treco

    Fredrik Tiberg

    CEO & President , Camurus
    Fredrik Tiberg

    Gregory T. Bourne

    Research Fellow , Protagonist Therapeutics
    Gregory  T. Bourne

    Ian Lewis

    Investigator III, Peptide Discovery Group, Exploratory Medicinal Chemistry Unit, Novartis Institutes of Biomedical Research
    Ian Lewis

    Joel Richard

    Senior Vice President, Peptides, IPSEN S.A.S
    Joel Richard

    Mark Currie

    President of R&D, Chief Scientific Officer, Ironwood Pharmaceuticals Inc
    Mark Currie

    Paul Watt

    CSO, Phylogica Ltd
    Paul  Watt

    Ved Srivastava

    Head, Peptide Chemistry, GSK
    Ved Srivastava

    Vincenzo Abbate

    Research Associate, Kings College London
    Vincenzo Abbate

    Yvonne Angell

    Director of Peptide and Protein Chemistry, Ipsen Inc.
    Yvonne Angell

    Speaker Q&A with Joel Richard, Senior Vice President, Peptides, IPSEN S.A.S

    Download

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.